TUESDAY, SEPTEMBER 19, 2023 |
|
---|---|
06:30 PM - 08:30 PM |
Opening Reception |
WEDNESDAY, SEPTEMBER 20, 2023 |
|
---|---|
09:00 AM - 10:00 AM |
Keynote Presentation Speaker: Suhail Alam, Head of Data and Analytics, Novartis IM International; Head of Data, Analytics and Insights, IM US |
10:00 AM - 10:45 AM |
Unlocking the Power of AI/ML: Essential Components for Success Speaker: Jaswinder Chadha, President & CEO, Axtria |
10:45 AM - 11:00 AM |
Break |
11:00 AM - 12:00 PM |
Panel Discussion: AI/ML and Advanced Analytics in Global Pharma Moderator: Igor Rudychev, President, PMSA Panelists: Suhail Alam, Head of Data and Analytics, Novartis IM International; Head of Data, Analytics and Insights, IM US; Jaswinder (Jassi) Chadha, President & CEO, Axtria; Simon Fitall, CEO, Tudor Health; Arif Nathoo, CEO, Komodo Health; Kilian Weiss, General Manager, Veeva Link, Veeva |
12:00 PM - 01:00 PM |
Lunch |
01:00 PM - 01:30 PM |
Understanding and Improving Vaccination Rates Speaker: Dan Pielak-Watkins, Executive Director, Business Engagement and Activation - Vaccines, HH Digital Data & Analytics, Merck |
01:30 PM - 02:00 PM |
From Proof of Concept to Production and Beyond for AI /NLP Solutions in Medical Affairs AI and NLP are universally applicable and malleable technologies that can be applied to many domains in the pharma industry, improving both patient outcomes and business performance. These tools offer invaluable insights from unstructured data, particularly in reporting and analytics for late stage and launched products. However, transitioning from a proof of concept (POC) to a productive environment presents challenges, especially in demonstrating the value of these AI/NLP solutions and establishing the role of the product owner an organization function with no prior experience. We will address transitioning from a POC to a productive environment including strategies for communication and cross-functional collaboration as well as strategies for quantifying and communicating the value of AI projects in the medical domain in the pharma industry. Finally, we will discuss the creation of a product owner role in an organization that has little experience of this role. We will outline the specific competencies, roles, and responsibilities, which may need to be acquired or developed within the organization. Additionally, we will discuss strategies for fostering a culture of innovation and collaboration is crucial to successfully implementing AI/NLP solutions. Speakers: Ben Collins, Global Capability Owner for Data Science and AI, Boehringer Ingelheim GmbH; Paolo Sammicheli, Scrum Trainer and Agile Coach, Boehringer Ingelheim GmbH; Jens Barthelmes, NLP Capability Lead, IT M&S, Boehringer Ingelheim GmbH |
02:00 PM - 02:30 PM |
Rare Disease EMR Data Case Study in Europe This presentation will focus on a case study showing how EMR-equivalent data provides high quality, longitudinal patient data to support product launch in an uncommon disease in four European countries. Uncommon disease background:
Detailed patient journey:
Data objectives:
The client need defined as follows:
Data capture and analysis. Proprietary data capture tools used to achieve:
Conclusions: This presentation will show how this method can be applied and shows how the method is being expanded by specialty and geography. Speakers: Simon Fitall, CEO, Tudor Health; Patrick Peristeri, MA, MBA, Director - International Analytics & Forecasting, Horizon Therapeutics |
02:30 PM - 02:45 PM |
Break |
02:45 PM - 03:15 PM |
The session will be focused on answering the following questions:
Speakers: Ankit Chhabra, Principal, Data Sciences, CustomerInsights.AI; Aditi Sachdeva, Associate Director, CustomerInsights.AI |
03:15 PM - 03:45 PM |
Oncological Patient Unmet Needs: A Data Science Approach to Refine Commercial and Medical Engagement Precision medicine powered by novel targeted therapies is revolutionizing oncology care for patients based on their protein expression levels and genomic phenotype. As the pharmaceutical landscape continues to evolve with these treatment advances, there has been a shift in strategy to focus more on improving patient health outcomes and equity. This shift in focus ensures that more patients receive best-in-class and optimal treatment. This requires health care providers to be more aware and empowered to administer comprehensive care based on the latest approved guidelines. Improving the ability to identify these unmet needs, both for patients as well as physicians, enables pharmaceutical organizations to become strategic partners in ensuring delivery of optimal care to patients. To adapt to these changes in practice, its important to understand the needs of both patients and physicians. Understanding deviations from optimal treatment and quantifying gaps in care can define priority focus areas for the pharma industry. These insights can impact clinical trial planning and enhance the specificity of commercial and medical initiatives including targeted educational programs. These insights will help define medical strategy and guide proactive and integrated evidence generation planning. Finally, the pharma industry can use these analyses to better plan their resource allocation and drive enhanced physician and patient engagement experiences. Speakers: Atharv Sharma, Advanced Data Science Manager, ZS Associates; Arrvind Sunder, Principal, ZS Associates; Daniel Young, Senior Director of Data Science and AI, AstraZeneca; Nate Lear, Head of Advanced Analytics and Clinical Field Efficiency US Medical Affairs, AstraZeneca |
03:45 PM - 04:45 PM |
Panel Discussion: Future of Pharmaceutical Analytics: Focusing on the Emerging Trends, Technologies, and Novel Data Sources that Will Shape the Industry Moderator: Nadia Tantsyura, Global Data Domain & Analytics Lead, Boehringer Ingelheim Panelists: Pini Ben-Or, Chief Science Officer, Aktana; Michel Christol, Global Capability Owner for Analytics & Performance Measurement, Boehringer Ingelheim; Konstantin Perederiy, SVP Sales/Digital Factory, Customertimes; Patrick Peristeri, Director - International Analytics & Forecasting, Horizon Therapeutics; Neeraj Sinha, Global Product Owner, Novartis |
06:00 PM - 08:00 PM |
Reception |
WEDNESDAY, SEPTEMBER 20, 2023 |
|
---|---|
09:00 AM - 10:00 AM |
Keynote Presentation Speaker: Suhail Alam, Head of Data and Analytics, Novartis IM International; Head of Data, Analytics and Insights, IM US |
10:00 AM - 10:45 AM |
Unlocking the Power of AI/ML: Essential Components for Success Speaker: Jaswinder Chadha, President & CEO, Axtria |
10:45 AM - 11:00 AM |
Break |
11:00 AM - 12:00 PM |
Panel Discussion: AI/ML and Advanced Analytics in Global Pharma Moderator: Igor Rudychev, President, PMSA Panelists: Suhail Alam, Head of Data and Analytics, Novartis IM International; Head of Data, Analytics and Insights, IM US; Jaswinder (Jassi) Chadha, President & CEO, Axtria; Simon Fitall, CEO, Tudor Health; Arif Nathoo, CEO, Komodo Health; Kilian Weiss, General Manager, Veeva Link, Veeva |
12:00 PM - 01:00 PM |
Lunch |
01:00 PM - 01:30 PM |
Understanding and Improving Vaccination Rates Speaker: Dan Pielak-Watkins, Executive Director, Business Engagement and Activation - Vaccines, HH Digital Data & Analytics, Merck |
01:30 PM - 02:00 PM |
From Proof of Concept to Production and Beyond for AI /NLP Solutions in Medical Affairs AI and NLP are universally applicable and malleable technologies that can be applied to many domains in the pharma industry, improving both patient outcomes and business performance. These tools offer invaluable insights from unstructured data, particularly in reporting and analytics for late stage and launched products. However, transitioning from a proof of concept (POC) to a productive environment presents challenges, especially in demonstrating the value of these AI/NLP solutions and establishing the role of the product owner an organization function with no prior experience. We will address transitioning from a POC to a productive environment including strategies for communication and cross-functional collaboration as well as strategies for quantifying and communicating the value of AI projects in the medical domain in the pharma industry. Finally, we will discuss the creation of a product owner role in an organization that has little experience of this role. We will outline the specific competencies, roles, and responsibilities, which may need to be acquired or developed within the organization. Additionally, we will discuss strategies for fostering a culture of innovation and collaboration is crucial to successfully implementing AI/NLP solutions. Speakers: Ben Collins, Global Capability Owner for Data Science and AI, Boehringer Ingelheim GmbH; Paolo Sammicheli, Scrum Trainer and Agile Coach, Boehringer Ingelheim GmbH; Jens Barthelmes, NLP Capability Lead, IT M&S, Boehringer Ingelheim GmbH |
02:00 PM - 02:30 PM |
Rare Disease EMR Data Case Study in Europe This presentation will focus on a case study showing how EMR-equivalent data provides high quality, longitudinal patient data to support product launch in an uncommon disease in four European countries. Uncommon disease background:
Detailed patient journey:
Data objectives:
The client need defined as follows:
Data capture and analysis. Proprietary data capture tools used to achieve:
Conclusions: This presentation will show how this method can be applied and shows how the method is being expanded by specialty and geography. Speakers: Simon Fitall, CEO, Tudor Health; Patrick Peristeri, MA, MBA, Director - International Analytics & Forecasting, Horizon Therapeutics |
02:30 PM - 02:45 PM |
Break |
02:45 PM - 03:15 PM |
The session will be focused on answering the following questions:
Speakers: Ankit Chhabra, Principal, Data Sciences, CustomerInsights.AI; Aditi Sachdeva, Associate Director, CustomerInsights.AI |
03:15 PM - 03:45 PM |
Oncological Patient Unmet Needs: A Data Science Approach to Refine Commercial and Medical Engagement Precision medicine powered by novel targeted therapies is revolutionizing oncology care for patients based on their protein expression levels and genomic phenotype. As the pharmaceutical landscape continues to evolve with these treatment advances, there has been a shift in strategy to focus more on improving patient health outcomes and equity. This shift in focus ensures that more patients receive best-in-class and optimal treatment. This requires health care providers to be more aware and empowered to administer comprehensive care based on the latest approved guidelines. Improving the ability to identify these unmet needs, both for patients as well as physicians, enables pharmaceutical organizations to become strategic partners in ensuring delivery of optimal care to patients. To adapt to these changes in practice, its important to understand the needs of both patients and physicians. Understanding deviations from optimal treatment and quantifying gaps in care can define priority focus areas for the pharma industry. These insights can impact clinical trial planning and enhance the specificity of commercial and medical initiatives including targeted educational programs. These insights will help define medical strategy and guide proactive and integrated evidence generation planning. Finally, the pharma industry can use these analyses to better plan their resource allocation and drive enhanced physician and patient engagement experiences. Speakers: Atharv Sharma, Advanced Data Science Manager, ZS Associates; Arrvind Sunder, Principal, ZS Associates; Daniel Young, Senior Director of Data Science and AI, AstraZeneca; Nate Lear, Head of Advanced Analytics and Clinical Field Efficiency US Medical Affairs, AstraZeneca |
03:45 PM - 04:45 PM |
Panel Discussion: Future of Pharmaceutical Analytics: Focusing on the Emerging Trends, Technologies, and Novel Data Sources that Will Shape the Industry Moderator: Nadia Tantsyura, Global Data Domain & Analytics Lead, Boehringer Ingelheim Panelists: Pini Ben-Or, Chief Science Officer, Aktana; Michel Christol, Global Capability Owner for Analytics & Performance Measurement, Boehringer Ingelheim; Konstantin Perederiy, SVP Sales/Digital Factory, Customertimes; Patrick Peristeri, Director - International Analytics & Forecasting, Horizon Therapeutics; Neeraj Sinha, Global Product Owner, Novartis |
06:00 PM - 08:00 PM |
Reception |